Primo Biotechnology
Taoyuan, Taiwan· Est.
Taiwan‑based radiopharmaceutical innovator delivering precision cancer diagnostics and therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan‑based radiopharmaceutical innovator delivering precision cancer diagnostics and therapeutics.
Oncology
Technology Platform
Proprietary radioligand theranostics platform combining a linker library with isotopes (Lu‑177, Tb‑161, F‑18) and automated GMP manufacturing for diagnostic and therapeutic applications.
Opportunities
Expansion into global oncology markets, leveraging proprietary linker chemistry and automated GMP capacity to attract partnership deals for next‑generation radioligand therapies.
Risk Factors
Regulatory approval timelines, isotope supply constraints, and competition from larger, well‑funded radiopharmaceutical companies.
Competitive Landscape
Competes with firms like Novartis, Lantheus, and IBA; differentiation stems from its proprietary linker library, flexible one‑drug‑one‑line manufacturing, and strong regional expertise in nuclear medicine.